Plain-English translation of NCT03516617 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , given either by itself or combined with another medication called , to treat people who have just been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma. Researchers want to see if adding the second medication helps more patients achieve a deep remission (where cancer cells are no longer detectable in bone marrow) and how well each approach works.
For patients at high risk of their cancer progressing quickly, doctors need better ways to achieve long-lasting remissions early on. This trial will help determine whether combining two medications works better than one medication alone, and whether it's safe and improves how long people stay cancer-free.
You likely qualify if…
You likely don't qualify if…
If you qualify and are assigned to the high-risk groups, you will take (a pill twice daily) for 6 months, then continue it at a lower frequency for another 6 months. If you're in the combination group, you'll also receive through an IV infusion during the first month, then once per month after that. You'll have regular blood tests and clinic visits to check how you're responding and watch for side effects. If you're in the lower-risk group, you'll be monitored closely without starting treatment right away, and researchers will track how long before you need therapy.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States